Pathological Response and Outcomes in Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Immunotherapy-Based Therapies and Undergoing Deferred Cytoreductive Nephrectomy (CN). [PDF]
Clin Genitourin CancerGunenc D +18 more
europepmc +1 more source
The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): study protocol for a multi-center, prospective, randomized trial. [PDF]
TrialsPark JS +11 more
europepmc +1 more source
Cytoreductive Nephrectomy in the Era of Targeted Therapies: A Review [PDF]
BJU International, 2017 In the pre‐targeted therapy era, palliative cytoreductive nephrectomy combined with cytokine immunotherapy was the standard treatment protocol for the management of metastatic renal cell carcinoma. The introduction of targeted therapies has improved response rates, median survival and overall prognosis when compared to immunotherapy.
Gideon Blecher, Nisha Pindoria
exaly +5 more sources
Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy [PDF]
European Urology, 2016 The authors report a single institution retrospective analysis of the reported complications and delay to initiation of systemic therapy in a cohort of 294 patients with metastatic renal cell carcinoma (1). This is the largest series evaluating this novel study question.
Boris Gershman +2 more
exaly +5 more sources
Related searches:
e15591 Background: Role of partial cytoreductive nephrectomy (PCN) for patients with metastatic renal cell carcinoma (mRCC) is still questionable nowadays.
Iuriy Vitruk +5 more
openaire +1 more source
Cytoreductive Nephrectomy — Patient Selection Is Key
New England Journal of Medicine, 2018Metastatic renal-cell carcinoma has diverse clinical presentations ranging from incidental detection to a highly symptomatic systemic illness. Patients with metastatic renal-cell carcinoma are assigned a risk category — favorable, intermediate, or poor — on the basis of two published models containing five or six pretreatment selection factors ...
Robert J, Motzer, Paul, Russo
openaire +2 more sources
Cytoreductive nephrectomy: A medical oncologist’s perspective
Urologic Oncology: Seminars and Original Investigations, 2017The role of cytoreductive nephrectomy (CN) was firmly established in the cytokine era on the basis of 2 randomized studies employing adjunctive interferon therapy. However, systemic therapy for metastatic renal cell carcinoma has evolved markedly over the past decade, with targeted therapies representing the standard of care in the front-line setting ...
Nazli, Dizman +2 more
openaire +2 more sources
Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma
Future Oncology, 2009Cytoreductive nephrectomy prior to cytokine therapy has a well-established role in the treatment of appropriately selected patients with metastatic renal cell carcinoma (RCC). Recent use of novel molecular targeted agents in the management of metastatic RCC has challenged the current dogma of treatment with regards to the necessity, patient selection ...
Edmund Chiong +2 more
exaly +3 more sources
The once and future role of cytoreductive nephrectomy
Urologic Oncology: Seminars and Original Investigations, 2008The role of nephrectomy in the setting of metastatic renal cell carcinoma has long been controversial and has continued to evolve over the last two decades. The practice of cytoreductive nephrectomy has only recently been widely accepted following the publication of 2 large multi-center randomized controlled trials that established a survival benefit ...
Mischel G, Neill, Michael A S, Jewett
openaire +2 more sources